FLNA
Filana Therapeutics, Inc. · Healthcare
Insiders bought $356K of Filana Therapeutics, Inc. in the last 12 months
1 insider bought on 2 days.
FLNA over the last year
Largest buyers, last 12 months
FLNA after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
2 insider filings since 2026, newest first
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.